Search research articles
Contact Us
Filters
Showing results (1641-1650 of 1,873) with videos related to
Page
of 188
Sort By:
European Journal of Heart Failure
|
September 2, 2022
Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
John W Ostrominski, Muthiah Vaduganathan, Brian L Claggett, et al.
Circulation
|
August 16, 2022
Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF
Kieran F Docherty, Paul Welsh, Subodh Verma, et al.
Journal of the American College of Cardiology
|
May 20, 2021
Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF
John R Teerlink, Rafael Diaz, G Michael Felker, et al.
JACC. Heart Failure
|
August 4, 2018
Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical Trials
Kishan S Parikh, Kavita Sharma, Mona Fiuzat, et al.
Circulation
|
April 20, 2022
Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF
Carly Adamson, Kieran F Docherty, Hiddo J L Heerspink, et al.
JACC. Heart Failure
|
July 1, 2017
Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial
Scott D Solomon, Adel R Rizkala, Jianjian Gong, et al.
ESC Heart Failure
|
February 19, 2026
Efficacy of aficamten according to geographic location of patients with hypertrophic obstructive cardiomyopathy
Caroline J Coats, Theodore Abraham, Roberto Barriales-Villa, et al.
The New England Journal of Medicine
|
April 1, 2014
Survival with cardiac-resynchronization therapy in mild heart failure
Ilan Goldenberg, Valentina Kutyifa, Helmut U Klein, et al.
The New England Journal of Medicine
|
April 11, 2014
Spironolactone for heart failure with preserved ejection fraction
Bertram Pitt, Marc A Pfeffer, Susan F Assmann, et al.
JAMA Cardiology
|
February 22, 2023
Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid-Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER
Jawad H Butt, Kieran F Docherty, Brian L Claggett, et al.
Page
of 188
Search research articles
Search
Showing results (1641-1650 of 1,873) with videos related to
Sort By:
Page
of 188
European Journal of Heart Failure
|
September 2, 2022
Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
John W Ostrominski, Muthiah Vaduganathan, Brian L Claggett, et al.
Circulation
|
August 16, 2022
Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF
Kieran F Docherty, Paul Welsh, Subodh Verma, et al.
Journal of the American College of Cardiology
|
May 20, 2021
Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF
John R Teerlink, Rafael Diaz, G Michael Felker, et al.
JACC. Heart Failure
|
August 4, 2018
Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical Trials
Kishan S Parikh, Kavita Sharma, Mona Fiuzat, et al.
Circulation
|
April 20, 2022
Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF
Carly Adamson, Kieran F Docherty, Hiddo J L Heerspink, et al.
JACC. Heart Failure
|
July 1, 2017
Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial
Scott D Solomon, Adel R Rizkala, Jianjian Gong, et al.
ESC Heart Failure
|
February 19, 2026
Efficacy of aficamten according to geographic location of patients with hypertrophic obstructive cardiomyopathy
Caroline J Coats, Theodore Abraham, Roberto Barriales-Villa, et al.
The New England Journal of Medicine
|
April 1, 2014
Survival with cardiac-resynchronization therapy in mild heart failure
Ilan Goldenberg, Valentina Kutyifa, Helmut U Klein, et al.
The New England Journal of Medicine
|
April 11, 2014
Spironolactone for heart failure with preserved ejection fraction
Bertram Pitt, Marc A Pfeffer, Susan F Assmann, et al.
JAMA Cardiology
|
February 22, 2023
Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid-Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER
Jawad H Butt, Kieran F Docherty, Brian L Claggett, et al.
Page
of 188